UNSPSC 51142658: Oxiracetam

This classification denotes a nutritional supplement and neuroprotective agent with the molecular formula C6H10N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P7U817352G, chemically known as 1-pyrrolidineacetamide, 4-hydroxy-2-oxo-, (s)- but generally known as oxiracetam, which bears US NIH Compound Identifier 4626. European Medicines Agency schedules Oxiracetam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09536MIG.

UNSPSC 51142658 Oxiracetam is a Commodity code for a specific pharmaceutical product, but recent state and local procurement activity under this code shows no direct solicitations for oxiracetam itself. Instead, the opportunities tagged to this code reflect broader pharmaceutical procurement — naloxone and drug deactivation systems for community health, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products distributed through cooperative purchasing vehicles. State and local governments buying under this code span county health departments, state health and human services commissions, and multi-state cooperative purchasing alliances. The work involves acquiring pharmaceutical products and related health-support systems for public health initiatives, emergency response capabilities, and employee or beneficiary pharmacy benefit programs.

Recent activity appears concentrated in the Southeast and upper Midwest, with visible procurement from Seminole County, Florida; Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) serving multiple states including Oregon. Representative solicitations include Seminole County's IFB60459723LAS, an Invitation for Bid posted June 30, 2026 with response due July 26, 2023 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program; and MMCAP's RFP S1070000015802, posted January 20, 2026 with proposals due March 26, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products through authorized wholesalers with products effective July 1, 2026. The code itself shows limited direct relevance to oxiracetam procurement — prospecting firms should monitor whether state and local bodies issue dedicated solicitations for branded or generic neurological pharmaceuticals or whether this code assignment represents a classification mismatch.